Skip to main content

First Turn Management, LLC

13F filer · CIK 0001993440
Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$935MU.S. long equity reported on 13F
Positions315 new · 7 closed
Net flow last quarter-$109MBuys minus sells
Top 10 positions weight53.6%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202631 positions
RVMDRevolution Medicines, Inc.$77.8M8.32%0.19%-11.3%Q2 2024
ABVXAbivax S.A.$65.3M6.98%0.62%+5.2%Q3 2025
AXSMAxsome Therapeutics, Inc.$53.5M5.72%0.42%+15.7%Q4 2023
ELVNEnliven Therapeutics, Inc.$48.4M5.18%1.30%+53.0%Q2 2024
BBIOBridgeBio Pharma, Inc.$47.2M5.05%0.32%-9.0%Q3 2024
ROIVRoivant Sciences Ltd.$47.1M5.04%0.18%+11.8%Q4 2023
UTHRUNITED THERAPEUTICS Corp$46M4.92%0.20%-18.9%Q3 2025
CYTKCytokinetics Inc$44.9M4.81%0.42%+85.9%Q4 2023
XENEXenon Pharmaceuticals Inc.$36.2M3.88%0.62%-23.7%Q4 2023
CELCCelcuity Inc.$34.4M3.68%0.67%+56.3%Q1 2026
VRDNViridian Therapeutics, Inc.\DE$30.7M3.28%1.47%+83.3%Q4 2025
INSMINSMED Inc$28.1M3.01%0.12%+6.2%Q2 2024
QUREuniQure N.V.$28M3.00%0.88%-1.1%Q4 2025
ASNDAscendis Pharma A/S$28M2.99%0.17%+37.5%Q4 2023
PRAXPraxis Precision Medicines, Inc.$28M2.99%0.30%+96.8%Q4 2024
DNTHDianthus Therapeutics, Inc.$27.9M2.98%0.52%+29.4%Q1 2026
PCVXVaxcyte, Inc.$25.8M2.76%0.31%Not reportedQ4 2023
MIRMMirum Pharmaceuticals, Inc.$25.5M2.73%0.34%-45.6%Q4 2023
PVLAPalvella Therapeutics, Inc.$23.9M2.56%1.09%+5.6%Q1 2026
COGTCogent Biosciences, Inc.$23.3M2.49%0.35%-36.4%Q4 2025
ERASErasca, Inc.$22.4M2.39%0.39%+40.8%Q1 2026
ORICOric Pharmaceuticals, Inc.$21.8M2.34%1.95%Not reportedQ1 2024
NAMSNewAmsterdam Pharma Co N.V.$19.7M2.11%0.50%+4.3%Q2 2025
APGEApogee Therapeutics, Inc.$18.4M1.97%0.18%-73.0%Q1 2024
RYTMRhythm Pharmaceuticals, Inc.$17.1M1.83%0.22%Not reportedQ4 2025
INBXInhibrx Biosciences, Inc.$15.6M1.67%1.12%NewQ2 2026
SRRKScholar Rock Holding Corp$14.9M1.60%0.22%-39.2%Q4 2025
ORKAOruka Therapeutics, Inc.$14.8M1.58%0.25%NewQ2 2026
KYMRKymera Therapeutics, Inc.$11.8M1.26%0.12%-59.7%Q3 2025
SIONSionna Therapeutics, Inc.$4.86M0.52%0.24%NewQ2 2026
NUVLNuvalent, Inc.$3.25M0.35%0.84%-92.9%Q4 2023
Q1 2026Reported May 15, 202633 positions
UTHRUNITED THERAPEUTICS Corp$62.1M6.94%0.25%+64.7%Q3 2025
ABVXAbivax S.A.$51.9M5.80%0.59%+22.2%Q3 2025
BBIOBridgeBio Pharma, Inc.$51.7M5.77%0.36%+16.8%Q3 2024
XENEXenon Pharmaceuticals Inc.$45.8M5.11%0.81%-1.6%Q4 2023
RVMDRevolution Medicines, Inc.$45.5M5.09%0.23%-26.6%Q2 2024
APGEApogee Therapeutics, Inc.$43.2M4.83%0.69%+8.2%Q1 2024
INSMINSMED Inc$40.6M4.54%0.11%-6.0%Q2 2024
NUVLNuvalent, Inc.$37.9M4.24%11.83%+0.5%Q4 2023
MIRMMirum Pharmaceuticals, Inc.$37M4.13%0.66%-16.8%Q4 2023
COGTCogent Biosciences, Inc.$36.5M4.07%0.55%+14.9%Q4 2025
ROIVRoivant Sciences Ltd.$33M3.68%0.17%+0.3%Q4 2023
AXSMAxsome Therapeutics, Inc.$31.9M3.56%0.37%-8.8%Q4 2023
IDYAIDEAYA Biosciences, Inc.$29.1M3.25%0.99%+20.8%Q4 2023
ORICOric Pharmaceuticals, Inc.$25.6M2.86%1.95%+0.4%Q1 2024
ELVNEnliven Therapeutics, Inc.$24.5M2.73%1.02%Not reportedQ2 2024
CELCCelcuity Inc.$24M2.69%0.44%NewQ1 2026
SRRKScholar Rock Holding Corp$21.9M2.45%0.37%-2.9%Q4 2025
KYMRKymera Therapeutics, Inc.$21.2M2.37%0.31%+23.4%Q3 2025
CYTKCytokinetics Inc$18.7M2.09%0.23%-12.9%Q4 2023
DNTHDianthus Therapeutics, Inc.$18.5M2.07%0.40%NewQ1 2026
PVLAPalvella Therapeutics, Inc.$18.5M2.06%1.03%NewQ1 2026
NAMSNewAmsterdam Pharma Co N.V.$17.9M2.00%0.48%-37.5%Q2 2025
VRDNViridian Therapeutics, Inc.\DE$17.8M1.99%0.89%+32.0%Q4 2025
ASNDAscendis Pharma A/S$17.5M1.95%0.12%-42.1%Q4 2023
FULCFulcrum Therapeutics, Inc.$17.3M1.93%3.39%+19.2%Q4 2025
TERNTerns Pharmaceuticals, Inc.$17.2M1.92%0.28%-62.5%Q4 2025
VERAVera Therapeutics, Inc.$17M1.90%0.66%-29.9%Q1 2024
NTRANatera, Inc.$16.2M1.81%0.06%+0.3%Q3 2024
ERASErasca, Inc.$14M1.57%0.28%NewQ1 2026
PRAXPraxis Precision Medicines, Inc.$13.7M1.53%0.15%+18.7%Q4 2024
OLMAOlema Pharmaceuticals, Inc.$11.5M1.28%0.88%+24.4%Q4 2025
QUREuniQure N.V.$10.1M1.12%0.98%+91.4%Q4 2025
MLTXMoonLake Immunotherapeutics$5.88M0.66%0.60%+20.2%Q1 2025
Q4 2025Reported Feb 13, 202633 positions
ABVXAbivax S.A.$51.4M5.87%0.49%+30.6%Q3 2025
RVMDRevolution Medicines, Inc.$50.8M5.81%0.32%-0.7%Q2 2024
INSMINSMED Inc$46M5.26%0.12%-17.4%Q2 2024
BBIOBridgeBio Pharma, Inc.$45.5M5.20%0.31%+1.0%Q3 2024
MIRMMirum Pharmaceuticals, Inc.$38M4.35%0.93%-15.6%Q4 2023
AXSMAxsome Therapeutics, Inc.$37.8M4.32%0.41%+35.6%Q4 2023
NUVLNuvalent, Inc.$37.1M4.24%11.78%-6.6%Q4 2023
XENEXenon Pharmaceuticals Inc.$35.8M4.10%1.00%Not reportedQ4 2023
APGEApogee Therapeutics, Inc.$35.8M4.10%0.69%+17.9%Q1 2024
TERNTerns Pharmaceuticals, Inc.$35.2M4.03%0.78%NewQ4 2025
NAMSNewAmsterdam Pharma Co N.V.$31.3M3.58%0.78%+24.6%Q2 2025
UTHRUNITED THERAPEUTICS Corp$31M3.54%0.15%-25.5%Q3 2025
VERAVera Therapeutics, Inc.$30.5M3.48%0.94%+69.7%Q1 2024
COGTCogent Biosciences, Inc.$29.3M3.35%0.51%NewQ4 2025
ASNDAscendis Pharma A/S$28.1M3.21%0.21%-9.9%Q4 2023
GHGuardant Health, Inc.$27.7M3.17%0.21%Not reportedQ1 2025
ROIVRoivant Sciences Ltd.$25.8M2.94%0.17%+23.7%Q4 2023
IDYAIDEAYA Biosciences, Inc.$25M2.86%0.82%Not reportedQ4 2023
VRDNViridian Therapeutics, Inc.\DE$21.5M2.46%0.68%NewQ4 2025
FULCFulcrum Therapeutics, Inc.$21.4M2.45%2.84%NewQ4 2025
CYTKCytokinetics Inc$20.7M2.36%0.26%+27.8%Q4 2023
SRRKScholar Rock Holding Corp$20.3M2.31%0.42%NewQ4 2025
ARGXArgenx SE$19.6M2.23%0.04%-40.0%Q4 2023
NTRANatera, Inc.$18.5M2.12%0.06%Not reportedQ3 2024
ORICOric Pharmaceuticals, Inc.$16.4M1.88%2.04%-6.9%Q1 2024
KYMRKymera Therapeutics, Inc.$16.1M1.84%0.25%-25.7%Q3 2025
RYTMRhythm Pharmaceuticals, Inc.$15.7M1.79%0.22%NewQ4 2025
OLMAOlema Pharmaceuticals, Inc.$15.4M1.76%0.76%NewQ4 2025
RCUSArcus Biosciences, Inc.$13.5M1.54%0.45%NewQ4 2025
IRONDisc Medicine, Inc.$12.2M1.39%0.40%-61.5%Q4 2023
PRAXPraxis Precision Medicines, Inc.$10.5M1.20%0.14%Not reportedQ4 2024
QUREuniQure N.V.$7.7M0.88%0.52%NewQ4 2025
MLTXMoonLake Immunotherapeutics$3.46M0.40%0.50%Not reportedQ1 2025
Q3 2025Reported Nov 14, 202529 positions
INSMINSMED Inc$46.1M6.91%0.15%-14.2%Q2 2024
MIRMMirum Pharmaceuticals, Inc.$41.8M6.28%1.11%+8.2%Q4 2023
UTHRUNITED THERAPEUTICS Corp$35.8M5.37%0.20%NewQ3 2025
MRUSMerus N.V.$35M5.26%0.49%+27.0%Q2 2024
NUVLNuvalent, Inc.$34.1M5.13%12.61%+23.1%Q4 2023
XENEXenon Pharmaceuticals Inc.$32.1M4.82%1.04%+21.1%Q4 2023
BBIOBridgeBio Pharma, Inc.$30.6M4.60%0.31%+6.9%Q3 2024
RVMDRevolution Medicines, Inc.$30M4.51%0.34%+54.7%Q2 2024
ASNDAscendis Pharma A/S$29.1M4.37%0.24%+8.6%Q4 2023
ARGXArgenx SE$28.6M4.29%0.06%-11.8%Q4 2023
IRONDisc Medicine, Inc.$26.3M3.95%1.14%+32.8%Q4 2023
ORICOric Pharmaceuticals, Inc.$25.9M3.89%2.22%+7.4%Q1 2024
ACLXArcellx, Inc.$25.8M3.87%0.54%+45.8%Q3 2024
NBIXNeurocrine Biosciences Inc$25.5M3.83%0.18%NewQ3 2025
ABVXAbivax S.A.$24.8M3.72%0.46%NewQ3 2025
NAMSNewAmsterdam Pharma Co N.V.$20.4M3.06%0.63%+37.6%Q2 2025
AKROAkero Therapeutics, Inc.$18.9M2.83%0.50%+246.6%Q2 2025
AXSMAxsome Therapeutics, Inc.$18.5M2.78%0.30%+5.7%Q4 2023
ELVNEnliven Therapeutics, Inc.$16M2.41%1.32%+53.6%Q2 2024
APGEApogee Therapeutics, Inc.$16M2.40%0.68%+29.3%Q1 2024
KYMRKymera Therapeutics, Inc.$15.7M2.36%0.39%NewQ3 2025
JANXJanux Therapeutics, Inc.$15.6M2.35%1.06%+43.0%Q4 2024
ROIVRoivant Sciences Ltd.$14.5M2.18%0.14%Not reportedQ4 2023
CYTKCytokinetics Inc$14M2.10%0.21%Not reportedQ4 2023
NTRANatera, Inc.$13M1.95%0.06%-31.5%Q3 2024
ADMAAdma Biologics, Inc.$11.9M1.78%0.34%-26.0%Q3 2024
VERAVera Therapeutics, Inc.$10.3M1.55%0.56%+14.5%Q1 2024
HROWHarrow, Inc.$7.72M1.16%0.43%-30.0%Q3 2024
MLTXMoonLake Immunotherapeutics$1.88M0.28%0.50%Not reportedQ1 2025
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.